SMAD2 and breast cancer: In summary, we have shown that AMPK by activation of metformin, AICAR, or LKB1 exerts a negative effect on TGF-β signaling, leading to inhibition of Smad2/3 activation and suppression of EMT and cell migration in breast cancer cells and precancerous mammary epithelial cells.